Technology evaluation: huN901-DM1 (ImmunoGen).

Simple item page
dc.contributor.authorSmith, SVen_AU
dc.date.accessioned2010-11-11T03:49:57Zen_AU
dc.date.available2010-11-11T03:49:57Zen_AU
dc.date.issued2005-07-25en_AU
dc.date.statistics2005-07-25en_AU
dc.description.abstractImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer. © 2005, Thomson Reutersen_AU
dc.identifier.citationSmith, S. V. (2005). Technology evaluation: huN901-DM1 (ImmunoGen). Current Opinion in Molecular Therapeutics, 7(4), 394-401.en_AU
dc.identifier.govdoc3048en_AU
dc.identifier.issn1464-8431en_AU
dc.identifier.issue4en_AU
dc.identifier.journaltitleCurrent Opinion in Molecular Therapeuticsen_AU
dc.identifier.pagination394-401en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/2848en_AU
dc.identifier.volume7en_AU
dc.language.isoenen_AU
dc.publisherThomson Reutersen_AU
dc.subjectEvaluationen_AU
dc.subjectNeoplasmsen_AU
dc.subjectLungsen_AU
dc.subjectCommercializationen_AU
dc.subjectDrugsen_AU
dc.subjectAntibodiesen_AU
dc.titleTechnology evaluation: huN901-DM1 (ImmunoGen).en_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles